Publications by authors named "Peter A Warn"

Claim this Profile
V
Vancomycin-arginine (STM-001) abrogates ESBL carrier and carbapenem-resistant Escherichia coli burden in a murine complicated urinary tract infection model.
Lewis F Neville, Itamar Shalit, Peter A Warn, Jacob T Rendell

J Antimicrob Chemother· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of the Fungus-Host-Microbiota interplay upon Candida albicans infections: current knowledge and new perspectives.
Christophe d'Enfert, Ann-Kristin Kaune, Leovigildo-Rey Alaban, Sayoni Chakraborty, Nathaniel Cole, Peter A Warn

FEMS Microbiol Rev· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Targeting of Escherichia coli with Vancomycin-Arginine.
Lewis F Neville, Itamar Shalit, Peter A Warn, Marc H Scheetz, Jiuzhi Sun

Antimicrob Agents Chemother· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRSA decolonization of cotton rat nares by a combination treatment comprising lysostaphin and the antimicrobial peptide ranalexin.
Andrew P Desbois, Abdul Sattar, Shirley Graham, Peter A Warn, Peter J Coote

J Antimicrob Chemother· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.
Ajay Sudan, Joanne Livermore, Susan J Howard, Zaid Al-Nakeeb, Andrew Sharp, Peter A Warn

Antimicrob Agents Chemother· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Aspergillus fumigatus dihydroxyacid dehydratase Ilv3A/IlvC is required for full virulence.
Jason D Oliver, Sarah J Kaye, Danny Tuckwell, Anna E Johns, Darel A Macdonald, Peter A Warn

PLoS One· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.
Adam R Jeans, Susan J Howard, Zaid Al-Nakeeb, Joanne Goodwin, Lea Gregson, Peter A Warn

Antimicrob Agents Chemother· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration.
Zaid Al-Nakeeb, Ajay Sudan, Adam R Jeans, Lea Gregson, Joanne Goodwin, Peter A Warn

Antimicrob Agents Chemother· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.
Adam R Jeans, Susan J Howard, Zaid Al-Nakeeb, Joanne Goodwin, Lea Gregson, Peter A Warn

J Infect Dis· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.
Peter A Warn, Joanne Livermore, Susan Howard, Timothy W Felton, Andrew Sharp

Antimicrob Agents Chemother· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoter.
Ahmed M Albarrag, Michael J Anderson, Susan J Howard, Geoff D Robson, Peter A Warn

Antimicrob Agents Chemother· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
Susan J Howard, Joanne Livermore, Andrew Sharp, Joanne Goodwin, Lea Gregson, Peter A Warn

Antimicrob Agents Chemother· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.
Susan J Howard, Jodi M Lestner, Andrew Sharp, Lea Gregson, Joanne Goodwin, Peter A Warn

J Infect Dis· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus.
Peter A Warn, Andrew Sharp, Graham Morrissey, David W Denning

Int J Antimicrob Agents· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
Peter A Warn, Andrew Sharp, Arvind Parmar, Jayesh Majithiya, David W Denning

Antimicrob Agents Chemother· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing.
William W Hope, Peter A Warn, Andrew Sharp, Paul Reed, Brian Keevil

Antimicrob Agents Chemother· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.
William W Hope, George L Drusano, Caroline B Moore, Andrew Sharp, Arnold Louie, Peter A Warn

Antimicrob Agents Chemother· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.
Peter A Warn, Andrew Sharp, Juan Mosquera, Jochen Spickermann, Anne Schmitt-Hoffmann

J Antimicrob Chemother· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect.
William W Hope, Peter A Warn, Andrew Sharp, Susan Howard, Miki Kasai

Antimicrob Agents Chemother· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.
Peter A Warn, Andrew Sharp, David W Denning

J Antimicrob Chemother· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis.
Peter A Warn, Andrew Sharp, Graham Morrissey, David W Denning

J Antimicrob Chemother· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis.
William W Hope, Peter A Warn, Andrew Sharp, Paul Reed, Brian Keevil

J Infect Dis· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida.
Peter A Warn, A Sharp, J Guinea, David W Denning

J Antimicrob Chemother· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis.
Peter A Warn, Andrew Sharp, Graham Morrissey, David W Denning

J Antimicrob Chemother· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis